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A B S T R A C T
Rationale: A substantial number of breast cancer patients with an overexpression of the human epidermal
growth factor receptor 2 (HER2) have residual disease after neoadjuvant therapy or become resistant to tras-
tuzumab. Photodynamic therapy (PDT) using nanobodies targeted to HER2 is a promising treatment option for
these patients. Here we investigate the in vitro and in vivo antitumor efficacy of HER2-targeted nanobody-pho-
tosensitizer (PS) conjugate PDT.
Methods: Nanobodies targeting HER2 were obtained from phage display selections. Monovalent nanobodies
were engineered into a biparatopic construct. The specificity of selected nanobodies was tested in immuno-
fluorescence assays and their affinity was evaluated in binding studies, both performed in a panel of breast
cancer cells varying in HER2 expression levels. The selected HER2-targeted nanobodies 1D5 and 1D5-18A12
were conjugated to the photosensitizer IRDye700DX and tested in in vitro PDT assays. Mice bearing orthotopic
HCC1954 trastuzumab-resistant tumors with high HER2 expression or MCF-7 tumors with low HER2 expression
were intravenously injected with nanobody-PS conjugates. Quantitative fluorescence spectroscopy was per-
formed for the determination of the local pharmacokinetics of the fluorescence conjugates. After nanobody-PS
administration, tumors were illuminated to a fluence of 100 J∙cm-2, with a fluence rate of 50 mW∙cm-2, and
thereafter tumor growth was measured with a follow-up until 30 days.
Results: The selected nanobodies remained functional after conjugation to the PS, binding specifically and with
high affinity to HER2-positive cells. Both nanobody-PS conjugates potently and selectively induced cell death of
HER2 overexpressing cells, either sensitive or resistant to trastuzumab, with low nanomolar LD50 values. In vivo,
quantitative fluorescence spectroscopy showed specific accumulation of nanobody-PS conjugates in HCC1954
tumors and indicated 2 h post injection as the most suitable time point to apply light. Nanobody-targeted PDT
with 1D5-PS and 1D5-18A12-PS induced significant tumor regression of trastuzumab-resistant high HER2 ex-
pressing tumors, whereas in low HER2 expressing tumors only a slight growth delay was observed.
Conclusion: Nanobody-PS conjugates accumulated selectively in vivo and their fluorescence could be detected
through optical imaging. Upon illumination, they selectively induced significant tumor regression of HER2
overexpressing tumors with a single treatment session. Nanobody-targeted PDT is therefore suggested as a
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T
new additional treatment for HER2-positive breast cancer, particularly of interest for trastuzumab-resistant
HER2-positive breast cancer. Further studies are now needed to assess the value of this approach in clinical
practice.
1. Introduction
Breast cancer is one of the most common cancers in women
worldwide. Despite increased understanding of its development and
progression, as well as advances in the development of novel ther-
apeutic strategies, breast cancer remains a clinical challenge. Human
epidermal growth factor receptor-2 (HER2) is overexpressed in 15–20%
of breast cancer patients, and results in a more aggressive disease with a
greater likelihood of recurrence [1,2]. In 1998, trastuzumab was in-
troduced as the targeted therapy for HER2-positive cancers. Trastu-
zumab is a recombinant, humanized monoclonal antibody, which re-
cognizes an epitope on subdomain 4 of HER2 extracellular domain [3].
At present, HER2-positive breast cancer is treated with HER2
blockade, such as trastuzumab, in the neoadjuvant, adjuvant, and me-
tastatic setting. Although the use of trastuzumab led to significant re-
duction of recurrence and mortality in HER2-positive breast cancer
patients [1,4], a substantial number of patients still had residual disease
after neoadjuvant therapy leading to a worse prognosis compared to
those who have no residual cancer [5–7]. Approximately a quarter of
patients who receive treatment for early breast cancer remain at risk of
relapse after 8–10 years, and around 15% of these patients will die
within a decade [8–10]. In addition, a significant number of patients
with HER2 overexpressing metastatic breast cancer are or will become
resistant to anti-HER2-based therapy with trastuzumab [11,12]. Pa-
tients with previously treated HER2-positive breast cancer have been
shown to benefit from new anti-HER2 therapies, as pertuzumab, lapa-
tinib, or the antibody-drug conjugate trastuzumab-emtansine [13–17],
suggesting that other drugs targeting HER2 might provide trastuzumab-
resistant patients with additional clinical benefit. In an attempt to de-
velop an additional treatment for HER2-positive breast cancer patients,
and in particular for trastuzumab-resistant patients, we have in-
vestigated a targeted form of photodynamic therapy.
Photodynamic therapy (PDT) has been employed in the clinic for
treatment of a range of cancers (e.g. skin, lung, bladder, head and neck,
and very recently primary breast cancer [18] and non-oncological
disorders (e.g. antimicrobial PDT, age-related macular degeneration)
[19]. PDT relies on the photosensitizing properties of a chemical
compound, i.e. a photosensitizer (PS), combined with light of a specific
wavelength, and oxygen present in close proximity to the PS. The PS
exposure to light converts nearby oxygen into singlet oxygen [20,21]
and other reactive oxygen species (ROS) which induce direct cellular
damage, resulting in cancer cell death via a variety of mechanisms that
include apoptosis and necrosis [20]. In addition, impairment of tumor-
associated vasculature and an immune response against cancer cells,
also contribute to tumor regression. Even though the activation of the
PS occurs locally, only where light is applied, the fact that conventional
PS are hydrophobic, and non-selective molecules, makes PDT often
associated with damage to surrounding normal tissue and unwanted
skin phototoxicity. The conjugation of more hydrophylic PS to con-
ventional monoclonal antibodies is currently being tested in the clinic
and reduces these unwanted effects, by specifically targeting the PS to
cancer cells [22,23].
Recently, we have been investigating an alternative approach for
targeted PDT, in which we conjugate the same PS as currently being
tested in the clinic (i.e. IRDye700DX) to nanobodies [24–28]. Nano-
bodies are the smallest naturally occurring, functional antigen binding
fragments of only 15 kDa, derived from heavy-chain only antibodies
present in Camelidae [29]. The advantage of nanobodies lies in the
combination of their small molecular size, with high binding affinity for
their targets. Such combination of features of labeled nanobodies re-
sults in high accumulation at the tumor site, better tumor penetration
and faster clearance from blood-circulation, as shown in a number of
cancer imaging studies [30–37], including HER2-positive breast cancer
tumors [38–42]. We therefore anticipate that, in the clinic, PDT em-
ploying nanobodies will lead to decreased skin and normal tissue
phototoxicity and will allow light application more rapidly after PS
administration (hours instead of days for antibody-based PS con-
jugates).
To date, we have shown that nanobody-PS conjugates bind selec-
tively to their target and upon illumination are able to induce selective
cell killing in vitro, in particular in cells overexpressing the target of
interest, such as EGFR [24,25], c-MET [26] or US28 [27], while not
affecting the low/negative or normal cells. In vivo, EGFR-targeted PDT
has shown to induce extensive tumor damage, as observed on tissue
sections processed from orthotopic tongue tumors collected 24 h post
PDT [25]. In addition, an intravital microscopy study has confirmed
that besides the direct damage to tumor cells, vascular effects are also
triggered by nanobody-targeted PDT [28]. These encouraging results
stimulated further research to assess, for the first time, the effect of
nanobody-targeted PDT on tumor growth over a month post therapy.
In this study, we have selected and characterized two monovalent
nanobodies (1D5 and 18A12) specifically targeting HER2, and have
constructed a biparatopic nanobody (1D5-18A12), to facilitate PS in-
ternalization as described previously [24,43]. The two most promising
nanobodies (1D5 and 1D5-18A12) were then conjugated to the trace-
able PS IRDye700DX, characterized in vitro and evaluated in nanobody-
targeted PDT for both trastuzumab-sensitive and -resistant breast
cancer cells. Next, two orthotopic breast cancer models were employed:
HCC1954, which is a trastuzumab-resistant HER2 overexpressing
model, and MCF-7, a low HER2 expressing model. Quantitative fluor-
escence spectroscopy was employed to follow the local pharmacoki-
netics of the fluorescent nanobody-PS conjugates, in order to determine
the optimal time-point for illumination. This was combined with optical
imaging to verify the accumulation of nanobody-PS conjugates in tu-
mors. Finally, the efficacy of nanobody-targeted PDT was evaluated in
both models by following tumor growth for 30 days after treatment.
2. Materials & methods
2.1. Phage display selection and production of anti-HER2 nanobodies
To select nanobodies specifically binding to human HER2 receptor,
two different and previously described phage display libraries were
panned on captured HER2 extracellular domain (MCF7L1 and
BT474L1) [44,45]. Briefly, anti-HER2 phages were selected on re-
combinant purified HER2-ECD containing a Fc tail, captured on a
Maxisorp plate (Nunc, Rochester, MN, USA) via rabbit-anti-human IgG
antibody (DakoCytomation, Glostrup, Denmark). Coated wells were
blocked with 4% milk powder in PBS for 1 h at room temperature (RT).
Phages pre-blocked with 4% milk-powder for 30 min at RT were
panned for binding to immobilized HER2-ECD. After extensive washing
with PBS/0.05% Tween-20, phages were eluted with trypsin (Sigma-
Aldrich, Saint Louis, MO, USA). The coding sequences of the obtained
nanobodies binding to the HER2 ectodomain were identified by per-
forming sequence analysis (Macrogen Inc., The Netherlands).
From these selections, two distinct nanobodies targeting HER2,
namely 1D5 and 18A12, were identified and employed in this study.
From the two nanobodies, a bivalent nanobody, i.e. 1D5-18A12, was
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constructed as nanobody-encoding genes were PCR amplified using the
Expand High Fidelity PCR System (Roche, Mannheim, Germany) with
an appropriate primer set, purified, cut with restriction enzymes, and
cloned into Sfi1-BstEII cut pET28A vector. Linker sequence (composed
of two Gly4-Ser (G4S) repeats) was encoded in the primers. Constructs
were sequenced to verify that no mutations were introduced by PCR.
These nanobodies were produced in E. coli and purified through im-
mobilized metal affinity chromatography (IMAC) as described pre-
viously [45].
2.2. Cell lines and culture conditions
Several human breast cancer cell lines were employed, which differ
in HER2 expression level and are either responsive or resistant to
trastuzumab treatment. HER2-positive breast cancer cell line SKBr3,
which is sensitive to trastuzumab treatment, and the HCC1419,
HCC1954, and JIMT1 cell lines, which are resistant to trastuzumab
treatment were employed. As control, the low HER2 expressing cancer
cell line MCF-7 and HER2-negative breast cancer cell line MDA-MB-231
were employed. JIMT1 cells were purchased from DMSZ (DSMZ GmbH,
Germany) and all other cell lines from the American Type Culture
Collection (ATCC, Manassas, VA, USA). All cells, except from HCC1419
and HCC1954 cells, were cultured in DMEM (Gibco) supplemented with
7.5% (v/v) FBS, 100 IU/ml penicillin, 100 mg/ml streptomycin, and
2 mM L-glutamine. HCC1419 and HCC1954 cells were maintained in
RPMI medium supplemented as described above.
2.3. Immunofluorescence
Two hundred thousand HER2 high or HER2 low expressing cells
were grown on coverslips for 2 days. On the day of the assay, cells were
washed with CO2-independent medium and incubated for 1.5 h at 4 °C
with a 50 nM solution of a nanobody (namely 1D5, 18A12, 1D5-
18A12). Unbound nanobodies were removed and cells were fixed with
4% paraformaldehyde (PFA). Bound nanobody was detected with
rabbit anti-VHH K1219 (1:1000 for 1 h at RT) (QVQ, Utrecht, The
Netherlands), followed by goat anti-rabbit Alexa 488 (1:1000 for 1 h at
RT) (Invitrogen, Breda, The Netherlands). Cell nuclei were stained with
DAPI (Roche, Almere, The Netherlands). Images were acquired using a
confocal laser scanning microscope LSM700 (Carl Zeiss Microscopy
GmbH) with a x63 oil objective (Plan-Apochromat 63×/1.40 Oil DIC
M27). Of note, difficulties in observing the individual cellular mem-
embranes were occasionally noticed, in particular for HCC1914, which
was attributed to more pronounced rounded morphology of cells that
coincided with rapid detachment of these cells.
2.4. Determination of apparent affinity of nanobodies on HER2-positive
cells
Binding studies were performed with the nanobodies on a panel of
HER2 expressing cells: SKBr3, HCC1954, JIMT1 and MCF-7 cells. The
HER2-negative cell line MDA-MB-231 was employed as control. Twenty
thousand cells were seeded per well 2 days in advance in 96-well plates.
Cells were incubated at 4 °C for 1.5 h with a dilution series of nano-
bodies in DMEM without phenol red, supplemented with 25 mM HEPES
and 1% BSA, pH 7.2 (binding buffer). Nanobodies were added in a
concentration range from 0.48 nM to 500 nM. After several washes cells
were fixed with 4% PFA for 30 min at RT and the fixative was quenched
by 10 min incubation with 100 mM glycine in PBS. The detection of
bound nanobodies was performed with the use of rabbit anti-VHH
protein G purified serum (1:1000 for 1 h at RT), followed by a goat anti
rabbit-IRDye800CW (1:1000 for 1 h at RT). The fluorescence signal was
detected using the 800 nm channel of the Odyssey scanner (LI-COR
Biosciences, Lincoln, NE, USA).
2.5. Conjugation of the PS IRDye700DX to the nanobodies and their
binding affinities
The two HER2-targeted nanobodies displaying the highest affinity
were randomly conjugated to the IRDye700DX (PS) (LI-COR
Biosciences) through an N-hydroxysuccinimidine (NHS) ester by cou-
pling to the primary amines of the nanobodies (i.e. N-terminal amino
acid and lysine residues) as described before [24]. Conjugation of the
PS was performed with a four-fold molar excess of PS for the mono-
valent nanobody and two-fold molar excess for the bivalent nanobody
for 2 h at RT. After conjugation, the unconjugated PS was removed
using sequentially two (in case of 1D5-18A12) or three (in case of 1D5)
Pierce ZebaTM Desalting Spin Columns. The degree of conjugation
(DoC) was determined according to the instructions given by the pro-
vider of the PS. The obtained PS conjugated nanobodies are referred to
as nanobody-PS (1D5-PS and 1D5-18A12-PS).
As random conjugation can have a detrimental effect on binding
properties of nanobodies [46], the apparent affinities of 1D5-PS and
1D5-18A12-PS were determined in binding studies on SKBr3,
HCC1954, and MDA-MB-231 cells. For this, the assay was performed as
described for the nanobodies except that the cell bound nanobody-PS
conjugates were detected directly through the PS fluorescence, after the
washing steps, using the 700 nm channel of the Odyssey scanner.
2.6. In vitro photodynamic therapy
One day after seeding 20.000 cells per well in 96-well plate (Greiner
Bio-One, Alphen a/d Rijn, The Netherlands), cells were washed with
DMEM without phenol red supplemented with 7.5% (v/v) fetal bovine
serum (FBS), 100 IU/ml penicillin, 100 mg/ml streptomycin and
2 mM L-glutamine (referred as PDT medium). Then cells were incubated
with a dilution series of nanobody-PS conjugates for 30 min at 37 °C
(short incubation time aimed to reflect nanobodies' short half-life).
After the incubation cells were washed twice with the PDT medium and
the detection of total fluorescence (i.e. bound and internalized fluor-
escence of the nanobody-PS conjugates) was performed immediately
afterwards using the Odyssey scanner. Thereafter, cells were illumi-
nated for 42 min with 4 mW∙cm−2 fluence rate for a total light dose of
10 J∙cm−2, using a custom-made device consisting of 96 LED lamps
(670± 10 nm, 1 LED per well), connected to a water bath thermostated
at 37 °C. An Orion Laser power/energy monitor (Ophir Optronics LTD,
Jerusalem, Israel) was used to measure and adjust the light intensity.
After illumination, cells were placed back in an incubator. In all ex-
periments, an internal negative control was included (those cells were
not subjected to illumination). Experiments were repeated at least
twice.
2.7. Cell viability assay
After an overnight post treatment incubation, cells were incubated
with Alamar Blue Reagent, according to the manufacturer's protocol
(AbD Serotec, Oxford, United Kingdom). The fluorescence was detected
with a Fluorostar 2 h after addition of the reagent. Results are expressed
as cell viability in percentage (%), relatively to the untreated cells. The
concentration of nanobody-PS conjugates subjected to illumination and
leading to 50% lethal dose (LD50) was determined using the GraphPad
Prism 5.02 software (GraphPad Software, San Diego, CA, USA).
2.8. Imaging of apoptotic and necrotic cells
Cellular morphology was assessed and apoptotic and necrotic cells
were distinguished with Annexin V-FITC and propidium iodide (PI)
staining, at different time points post illumination. HER2-positive
(HCC1954) and HER2 low expressing (MCF-7) cells were seeded in 96-
wells plates one day before the incubation with 25 nM nanobody-PS
followed by illumination (10 J∙cm−2 of light dose). Apoptotic cells were
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detected with Annexin V-FITC (BioLegend, San Diego, CA, USA),
whereas necrotic cells were detected with PI (Invitrogen), either 1 h or
24 h after light application. Cells were incubated with 10 μM
Staurosporine (Sigma-Aldrich) for 24 h as a control for apoptotic cell
death, while 1% Triton X-100 (Sigma-Aldrich) was incubated with cells
for 3 h to permeabilize cells, mimicking necrosis. Images were taken
using the bright field, GFP and RFP channels on the EVOS Microscope
(Advanced Microscopy Group, AMG, Thermo Fischer Scientific)
equipped with 10× objective (Plan Fluor, 10×, NA 0.3, Air and
working distance 8.3 mm, AMG) as described before [24].
2.9. Animal model
Nude CD-1 (Crl:CD1-Foxn1nu) female mice (Charles River labora-
tories, l'Arbresle, France), aged 4–6 weeks, were housed in individually
ventilated cages and provided with food and sterilized water ad libitium.
Animal experiments were approved by the local animal welfare com-
mittee of the Leiden University Medical Center. Under general an-
esthesia, a small incision between the fourth and fifth nipple was made,
bilaterally. The mammary fat pads were exposed and subsequently
3 × 106 HCC1954 cells (high HER2 expressing and trastuzumab-re-
sistant) or 0.5 × 106 MCF-7 cells (low HER2 expressing), were injected
in a 30 μl volume (PBS) into the mammary gland bilaterally. Thereafter,
the skin was closed with sutures. General animal health was checked
three times a week by weight measurements and inspection of the ab-
domen. Tumor growth was monitored three times a week by mea-
surement with digital calipers and tumor volume (mm3) was de-
termined with the formula length × width2 × 0.52. Experiments were
started when the tumors reached a volume of approximately
100–130 mm3 and the treatment volume was defined 100%.
Fig. 1. The selected nanobodies are HER2 specific. A. The HER2 overexpressing cell lines; SKBr3, HCC1419 and HCC1954, and the low HER2 expressing cell line
JIMT1 and MCF-7, were incubated with the nanobodies, monovalent (1D5 and 18A12) or bivalent (1D5-18A12), at 50 nM concentration, and imaged using confocal
microscopy (same imaging settings for each cell line, scale bar = 20 μm). B. All selected nanobodies bind to cell lines according to their HER2 expression level:
HCC1954 > SKBr3 > JIMT1 and not to MDA-MB-231 cells. Detection of bound nanobodies was performed through primary and secondary antibodies, fluores-
cence intensity at 800 nm.
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2.10. Quantitative fluorescence spectroscopy in vivo
To determine the optimal time point for illumination, quantitative
fluorescence spectroscopy was performed as described previously
[25,47]. Mice were randomly divided into two groups and received
100 μg of 1D5-PS intravenously. After verifying 1D5-PS accumulation
in HER2 overexpressing tumors, only mice with HCC1954 tumors
received 200 μg of 1D5-18A12-PS (all groups consisting of 2–3 mice,
each mouse receiving approximately 6 nmol of PS to allow compar-
ison). Quantitative fluorescence spectroscopy measurements were per-
formed 0.5, 1, 2 and 4 h after injection of the conjugates under iso-
flurane anesthesia. The tumor was exposed by a small incision in the
inguinal skin. Care was taken to position the fiber probe on the tumor.
Between measurements the skin was closed with sutures. Measurements
Fig. 2. Nanobody-PS conjugates bind to cell lines according to their HER2 expression levels and upon illumination induce cytotoxicity to cells with high HER2
expression. A. Dilution series of 1D5-PS and 1D5-18A12-PS were incubated with cells for 1 h 30 min at 4 °C to determine apparent affinity. Bound nanobodies are
directly detected through fluorescence of the PS. B. Total fluorescence intensity associated with cells after 30 min incubation at 37 °C with a concentration range of
1D5-PS or 1D5-18A12-PS. C. Cell viability determined 24 h after illumination with 10 J∙cm−2. PDT with HER2 overexpressing cells and low HER2 expressing cells
and 1D5-PS or 1D5-18A12-PS.
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were performed in triplicate on the tumor, ipsilateral normal mammary
gland (behind the second nipple), and skin. The resulting intrinsic
fluorescence signals, expressed as Q·μfa,x where Q is the fluorescence
quantum yield of the conjugate, was statistically analyzed using the
GraphPad Prism 5.02 software. Analysis of significance was performed
by unpaired Student's t-test and differences with p-values< .05 were
considered significant.
2.11. In vivo optical imaging and photodynamic therapy
Mice were divided in three groups for each tumor model, receiving
in 100 μl of PBS in the tail vein: a. 100 μg 1D5-PS (n = 8 HCC1954,
n = 7 MCF-7), b. 200 μg 1D5-18A12-PS (n = 13 HCC1954, n = 6 MCF-
7), or c. vehicle as control (n = 11 HCC1954, n = 9 MCF-7), including
tumors exposed to illumination only (n = 2 HCC1954, n = 1 MCF-7).
Fifteen minutes before illumination, and under anesthesia with iso-
flurane, optical imaging of the fluorescence of the nanobody-PS con-
jugates was performed with the Pearl Trilogy Small Animal Imaging
System (LI-COR Biosciences) to access the accumulation of the nano-
body-PS in both tumor models.
Subsequently, at the best time point selected through quantitative
fluorescence spectroscopy, mice were brought in a dark room, under
isoflurane anesthesia and received a subcutaneous injection of a pain-
killer. The area surrounding the tumor was covered with black paper to
protect the animal from any scattered laser light. The unilaterally breast
tumors were then illuminated using a 690 nm diode laser (Modulight,
Tampere, Finland). The power at the end of the optic fiber was cali-
brated with a power meter (Gigahertz optic, Turkenfeld, Germany).
Light was delivered via a 600 μm optic fiber with a fluence rate of
50 mW∙cm−2. The exposure time was adjusted to obtain a fluence of
100 J∙cm−2. Tumor growth was measured with a caliper, three times a
week, until 30 days after treatment or until the (contralateral) tumor
reached the maximum size of 750 mm3. Mice were sacrificed by in-
duction of anesthesia with isoflurane followed by cervical dislocation.
2.12. Tumor volume and statistical analysis
Tumor volume values are expressed as means± standard deviation
(SD). The short term effect of PDT was evaluated 3 days after illumi-
nation. The regression and/or growth of the tumor at the long term
after PDT was determined by linearly interpolating the points in time at
which the tumor reached a volume of respectively 50, 100, 200, 300,
400 and 500% using the equation y = A.e(b.x) where, before treatment,
A, is the size of the tumor at day 0 (set to 100%) and b is the tumor
growth rate. After the treatment, A, can be related to the fraction of
cells that survive PDT. The effectiveness of the treatment was de-
termined by comparing the mean volume doubling time (time to grow
to 200%) and the time to regrow to 100%. The percentage of tumors
that have not doubled in volume (tumors not reaching 200% of their
original volume 30 days after PDT) was determined and analyzed by a
Kaplan-Meier survival curve. Data was statistically analyzed using the
GraphPad Prism 5.02 software for Windows (GraphPad Software, San
Diego, CA, USA). Analysis of significance was performed by Student's t-
test (between 2 treatment groups) and one-way ANOVA (for> 2
treatment groups) and differences with p-values< .05 were considered
significant.
3. Results
3.1. Selected nanobodies bind specifically and with high affinity to HER2
Two nanobodies that bind to HER2 were selected and further
characterized: 1D5 from the MCF7L1 immune library and 18A12 from
the BT474L1 immune library. These two nanobodies were further en-
gineered into a biparatopic nanobody, 1D5-18A12 (Fig. S1A). The aim
of developing a biparatopic nanobody was to favor the accumulation of
the photosensitizer inside the cell, as previously observed with other
nanobody-photosensitizer conjugates [23]. To demonstrate that the
selected nanobodies recognize non-overlappiong epitopes, a competi-
tion assay was performed. As the excess of one of them did not affect
the binding of the other phage, we conclude that the two nanobodies
bind non-overlapping epitopes and can be used for producing a bipar-
atopic anti-HER2 nanobody (Fig. S1B).
A panel of breast cancer cell lines was assembled which varied in
HER2 expression and sensitivity to trastuzumab. SKBr3, HCC1954 and
HCC1419 are high HER2 expressing cells, JIMT1 and MCF-7 have a low
HER2 expression level, and MDA-MB-231 cells are considered negative
for HER2 expression (Fig. S2AB). Of these, only SKBr3 cells are sensi-
tive to trastuzumab treatment (Fig. S2C). The binding specificity of the
three nanobodies was observed by immunofluorescence with a clear
fluorescent signal at the cell membrane of cells highly expressing HER2,
namely SKBr3, HCC1419 and HCC1954, whereas a very faint fluores-
cence signal was detected for all nanobodies on MCF-7 cells, and almost
no fluorescence signal on JIMT1 cells (Fig. 1A). These nanobodies do
not compete for the binding epitope with trastuzumab (data not
shown).
Very high binding affinities to HER2-positive cells were observed for
the three nanobodies: for 1D5 affinities of 4.1 ± 1.7 nM in SKBr3 cells
and 2.1 ± 0.4 nM in HCC1954 cells were observed, whereas for 18A12
a slightly lower affinity was observed: 11.5 ± 4.0 nM in SKBr3 cells
and 16.7 ± 4.9 nM in HCC1954 cells, respectively (Fig. 1B). A high
affinity was also obtained for the biparatopic nanobody: 3.1 ± 0.6 nM
in SKBr3 cells and 4.6 ± 0.6 nM in HCC1954 cells. Importantly, no
binding was detected to the HER2-negative MDA-MB-231 cells, not
even at the highest concentrations of 500 nM, which demonstrates
specific binding to HER2. To JIMT1 and MCF-7 cells only very low
binding was observed with the biparatopic nanobody, which correlates
with the low HER2 expression level (Fig. S2B). The differences in the
extent of maximum binding (Bmax) between HCC1954 and SKBr3 likely
reflect differences in epitope availability, as the HER2 expression de-
termined by western blotting was only slightly higher in HCC1954 cells
(Fig. S2B).
Internalization of these HER2-targeting nanobodies was assessed
using radio-labeled nanobodies incubated with SKBr3 cells as described
previously [43]. The 18A12 nanobody showed a slightly higher inter-
nalization rate constant (ke), as compared to 1D5, while the biparatopic
nanobody 1D5-18A12 showed a ten-fold increase in internalization,
compared to 1D5 (Fig. S3). These results are in agreement with pre-
vious results using biparatopic anti-EGFR nanobodies [43]. The elec-
tron microscopy data further supports the internalization of both 1D5
and 1D5-18A12 nanobody (Fig. S4).
3.2. Nanobody-PS conjugates retain their binding properties
The photosensitizer IRDye700DX (PS) was subsequently conjugated
to 1D5 and 1D5-18A12. The success of conjugation was examined by
SDS-PAGE, which also showed the remaining free PS. All nanobody-PS
preparations contained less than 10% of free PS (Fig. S5A). The degree
of conjugation (DoC) was close to one for both nanobody-PS conjugates
and this process was reproducible. The apparent binding affinities (KD)
of both 1D5-PS and 1D5-18A12-PS were only slightly affected, with
values of: 8.2 ± 0.9 nM and 7.8 ± 0.9 nM on SKBr3 cells, and
5.4 ± 0.9 nM and 10.1 ± 1.1 nM on HCC1954 cells, respectively
(Fig. 2A). Overall, both nanobody-PS conjugates remained able to bind
with low nanomolar affinities to HER2 present on trastuzumab-sensi-
tive cells (SKBr3 cells), and on trastuzumab-resistant cells (HCC1954),
while no binding was observed to the negative cells (MDA-MB-231),
which correlates with expression levels of HER2 (Fig. S2B).
3.3. Nanobody-PS conjugates are potent and selective PDT agents
The association of the conjugates with the different cell lines at
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37 °C also correlated well with their HER2 expression level (Fig. 2B).
After illumination for PS activation, both nanobody-PS showed to be
very potent and capable of inducing cell death, specifically on cell lines
with high HER2 expression. The LD50 of 1D5-18A12-PS determined on
SKBr3 cells was 3.1 ± 1.7 nM, on HCC1954 1.8 ± 1.5 nM and on
HCC1419 1.7 ± 0.5 nM (Fig. 2C). Interestingly, for 1D5-PS, the LD50
determined was 2 to 3 times higher than for 1D5-18A12-PS: on SKBr3
cells LD50 was 7.2 ± 3.4 nM, on HCC1954 5.5 ± 1.9 nM, and on
HCC1419 4.7 ± 0.9 nM (Fig. 2C). Notably, both nanobody-PS caused
no toxicity on low HER2 expressing MCF-7 cells, which was in agree-
ment with binding assays (Fig. 1B) and incubation data (Fig. 2B), and
confirmed the selectivity of nanobody-targeted PDT. Moreover, as we
have clearly demonstrated in previous studies [24,25], nanobodies
alone, PS alone, or nanobody-PS without illumination had no effect on
the viability of SKBr3 and HCC1954 cells (Fig. S5B). In addition, tox-
icicty could be reduced by sodium azide, a singlet oxygen quencher
(data not shown).
For both 1D5-PS and 1D5-18A12-PS, as early as 1 h after illumi-
nation, some cell damage was observed in phase contrast images, which
was accompanied with PI staining of a fraction of HCC1954, suggesting
necrosis. The toxic effect increased with time, as shown by the increase
of PI staining at 24 h compared to 1 h post illumination (Fig. 3). The
majority of cells were also positive for Annexin-V, indicating apoptosis,
although the rapid and concomitant staining with PI suggests necrosis.
In addition, there is a clear difference in morphology of cells that are
only undergoing apoptosis (Staurosporine control), compared to the
effect induced by nanobody-targeted PDT.
3.4. Quantitative fluorescence spectroscopy and optical imaging show
specific accumulation of nanobody-PS conjugates in high HER2 expressing
tumors
Inoculation with either HCC1954 cells or MCF-7 cells led to the
development of orthotopic breast tumor models with high and low
HER2 expression, respectively, as confirmed through histological as-
sessment (Fig. S6A).
Both nanobody-PS conjugates were found in a higher degree in
HCC1954 tumors compared to the ipsilateral mammary gland (without
tumor) and skin, verifying the tumor specificity of these conjugates
(Fig. 4A). Differences in quantitative fluorescence between tumor and
normal mammary gland were statistically significant (p < .05) at time
point 1 h post injection for both nanobody-PS (respectively tumor vs
mammary gland 1D5-PS: Q · μfa,x = 3.24 × 10−3 vs 1.40 × 10−3 and
Q·μfa,x = 18A12-PS: 2.35 × 10−3 vs 1.20 × 10−3) and at 2 h post
injection only for 1D5-PS (tumor vs mammary gland 3.56 × 10−3 vs
1.83 × 10−3). At 1 and 2 h after injection, there was no significant
difference between quantitative fluorescence of 1D5-PS and 1D5-
18A12-PS present in HCC1954 tumors. Importantly, the quantitative
Fig. 3. Nanobody-targeted PDT induces changes in morphology and cell death. HER2-positive HCC1954 were incubated with 25 nM nanobody-PS, 1D5-PS (upper left
row) and 1D5-18A12 (lower left row), followed by light illumination (10 J/cm2 of light dose). Apoptotic cells were detected with Annexin V-FITC (green), whereas
necrotic cells with propidium iodide (red) staining 1 h and 24 h after light illumination. The increase of propidium iodide staining shows the toxic effect of PDT
increased between 1 h and 24 h. As a control for apoptotic and necrotic cell death, non-treated HCC1954 cells were incubated with Staurosporine or Triton
respectively (right row). Pictures were obtained with an EVOS Microscope equipped with 10× objective. Scale = 20 μm. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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fluorescence of 1D5-PS and 1D5-18A12-PS at 2 h post injection was
significantly higher in HCC1954 tumors than that of 1D5-PS in MCF-7
tumors (3.07 × 10−4, respectively p < .001 and p < .05), verifying
the selectivity of these conjugates to high HER2 expressing tumors. The
maximum quantitative fluorescence of 1D5-PS and 1D5-18A12-PS was
observed at 2 h post injection, after which the intrinsic fluorescence
decreased. No significant differences were observed in normal skin
tissue between 1D5-PS conjugates in HCC1954 and MCF-7 tumors.
Based on these quantitative fluorescence spectroscopy measurements,
2 h post injection was the time point chosen to apply light for PDT.
Optical imaging at 700 nm performed 15 min before the illumina-
tion time point also confirmed the accumulation of 1D5-PS and 1D5-
18A12-PS in the high HER2 expressing model (Fig. 4B). In contrast, in
the low HER2 expressing tumors no or clearly less accumulation of
either nanobody-PS conjugates was observed. In addition, fluorescence
was non-invasively detected in the kidneys, bladder, and liver. Al-
though no biodistribution study was here conducted, the presence of
fluorescence in these organs was expected, based on previous
biodistribution studies with nanobodies [45]. Together, the quantita-
tive fluorescence spectroscopy and optical imaging showed that the
conjugates accumulate specifically in the high HER2 expressing breast
tumor model.
3.5. Nanobody-targeted PDT induces tumor regression of high HER2
expressing breast tumors after a single treatment session
The average size of HCC1954 tumors at the day of PDT (day 0) was
93 ± 20 mm3 (1D5-PS) and 142 ± 21 mm3 (1D5-18A12-PS), for
MCF-7 tumors the average size was and 128 ± 7 mm3 (1D5-PS) and
153 ± 58 mm3 (1D5-18A12-PS). The average tumor size of HCC1954
tumors treated with 1D5-PS PDT were somewhat smaller than
HCC1954 tumors treated with 1D5-18A12-PS PDT (p < .05). An
overview of the treatment schedule is represented in Fig. 5A. Skin le-
sions with scarring, edema or necrosis were seen 2 days after PDT in
mice treated with 1D5-PS and 1D5-18A12-PS and illumination and at
location of HCC9154 and MCF-7 tumors. These lesions were all self-
Fig. 4. Quantitative fluoresence spectroscopy and fluorescence images after intravenous injection of nanobody-PS. A. The quantitative fluorescence of 1D5-PS and
1D5-18A12-PS at 2 h post injection was significantly higher in HCC1954 tumors than of 1D5-PS in MCF-7 tumors (respectively p < .001 and p < .05). The
maximum amount of 1D5-PS and 1D5-18A12-PS was observed at 2 h post injection. B. Fluorescence images (at 700 nm) of mice bearing MCF-7 (A + B) or HCC1954
(C + D) tumors, 1 h 45 after intravenous injection of 1D5-PS or 1D5-18A12-PS, showing accumulation of both nanobody-PS in tumors with high HER2 expression. In
contrast, in the low HER2 expressing tumors none or less accumulation of both nanobody-PS is shown. Beside tumor uptake, uptake of the nanobody-PS was also seen
in the bladder, as the clearance of the nanobody-PS is through the kidneys, and liver. *Orthotopic breast tumor in situ.
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limiting one week after PDT. Besides skin lesions, no other side effects
of PDT were seen.
The high expressing HER2 tumors (HCC1954) showed a significant
tumor volume reduction after both nanobody-PS mediated PDT treat-
ments, compared to control tumors (p < .001), which was not sig-
nificantly different for the two nanobody-PS conjugates investigated
(p = .65) (Fig. 5B). Three days post treatment the tumor volume was
reduced to 27.2% ± 14.5 for 1D5-PS and 50.1% ± 24.9 for 1D5-
18A12-PS mediated PDT, whereas the control showed growth to
112.8% ± 4.2. These results are supported by the decreased cell
proliferation observed 24 h post PDT, through the low intensity of Ki67
staining, compared to the control (Fig. S7). Control HCC1954 tumors,
receiving no nanobody-PS or light, showed a mean volume doubling
time of 19 ± 6 days. After 1D5-PS mediated PDT only 1 out of 7 tu-
mors (14%) grew back to more than 100% and growth was delayed by
22 days (Fig. 5C). While the tumor in the other 6 animals did not reach
100%, tumor growth was delayed by more than 30 days. After 1D5-
18A12-PS mediated PDT, 5 out of 12 tumors (42%) grew back to 100%
within 21 ± 7 days. The growth of the tumor in the other 7 animals
did not reach 100%, and the tumor growth was delayed by more than
30 days. The follow-up of four mice with a HCC1954 tumor (treated
with 1D5-PS PDT; n = 3 and 1D5-18A12-PS PDT; n = 1) was shorter
than 30 days due to a maximum tumor size on the contralateral side
(Fig. 5C).
The low HER2 expressing tumor model showed no regression of
tumor volume after nanobody-targeted PDT (Fig. 5B). The mean tumor
volume at day 3 after PDT was 111.9% ± 19.0 after 1D5-PS and
114.7% ± 13.4 after 1D5-18A12-PS mediated PDT compared to
145% ± 12.1 for the controls. These results are also supported by the
decreased cell proliferation observed through low intensity of Ki67
staining, 24 h post PDT compared to the control group (Fig. S7). No-
tably, after day 3, tumor growth resumed at a similar rate as the un-
treated tumors. The growth of MCF-7 tumors injected with 1D5-PS or
1D5-18A12-PS followed by illumination, was not significantly different
from the tumors in their control group (p = .13). Control MCF-7 tu-
mors, receiving no nanobody or light, showed a mean volume doubling
Fig. 5. Nanobody-PS photodynamic therapy induced tumor regression in high HER2 expressing breast tumors. A. Experimental protocol of photodynamic therapy in
vivo. Injection of nanobody-PS conjugates was performed at time 0, imaging with Pearl Imaging System at 1 h 45 and illumination was performed 2 h after injection.
B. Mice injected with 1D5-PS (n = 8 HCC1954, n = 7 MCF-7) or 1D5-18A12-PS (n = 13 HCC1954, n = 6 MCF-7), or vehicle as control (n = 11 HCC1954, n = 9
MCF-7), were subsequently illuminated and tumor growth monitored, here depicted in percentage. Day 0 as day of illumination. C. Kaplan Meier curve of the
percentage of tumors that have not double in volume (200%) after 30 days.
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time of 6 ± 1 days. After 1D5-PS mediated PDT the mean volume
doubling time was 8 ± 2 days compared to 9 ± 3 days after 1D5-
18A12-PS mediated PDT (Fig. 5C).
4. Discussion
The aim of this study was to investigate an alternative treatment
option for breast cancer patients, in particular trastuzumab-resistant
cancers. For that we have developed nanobody-PS conjugates targeting
HER2 that are capable of binding specifically and with high affinities to
this receptor on both trastuzumab-sensitive and -resistant cell lines.
Upon illumination of nanobody-PS associated with cells, selective cy-
totoxicity was induced in HER2 overexpressing cells, whereas the HER2
low expressing cells remained unaffected. Quantitative fluorescence
spectroscopy and optical imaging confirmed that the nanobody-PS ac-
cumulate specifically in the high HER2 expressing breast tumor model,
and indicated 2 h post injection as most suitable time point for illu-
mination. Importantly, the efficacy of nanobody-based PDT was con-
firmed in vivo, where significant tumor regression was observed for the
high HER2 expressing tumors, while only a slight growth delay of
2–3 days was induced in the low HER2 expressing tumors. In fact, at
day 3 after PDT mediated with 1D5-PS, HCC1954 tumor sizes were
reduced to a third of their original size, and 6 out of 7 tumors did not
regrow. Considering this significant tumor regression was induced in
the high HER2 expressing model after a single treatment only, the
present study demonstrates not only the selectivity, but also the po-
tency of nanobody-targeted PDT.
To our knowledge, this is the first study in which the potential of
HER2-targeted PDT was evaluated for treatment of both trastuzumab-
sensitive and trastuzumab-resistant breast cancer cells. Our in vitro re-
sults, conducted with a panel of different breast cancer cell lines,
showed that nanobody-targeted PDT is potent and selective. Other
approaches have been investigated for targeted PDT in breast cancer. In
comparison to using peptide-based factor VII-targeted veterpforin PDT
of breast cancer cells, nanobody-targeted PDT showed efficacy (LD50) at
1000-fold lower concentration, even with a six times lower total light
dose [48,49]. Stuchinskaya et al. and Obaid et al. have also shown a
significantly decreased viability of HER2 overexpressing SKBr3 cells
after treatment with anti-HER2 antibody conjugated gold nanoparticles
and irradiation [50,51]. However, this was reached with still 40% of
the cells remaining alive (with the same conditions as light dose and
conjugate concentration as the present study) [50] or a 10 to 100 fold
higher concentration of the PS conjugates [51]. Although a comparison
to other targeted PDT of breast cancer cells is difficult due to difference
in the setting of experiments, including cell conditions, the differences
in LD50 after nanobody-based PDT are encouraging.
We have previously shown that internalizing nanobodies are more
effective in in vitro PDT assays than the nanobodies that remain at the
cell surface [23], which is also in line with other reports using inter-
nalizing versus non-internalizing antibody-PS conjugates [47–49]. In-
ternalization of PS was achieved by employing a biparatopic nanobody,
which is known to promote receptor-mediated internalization [43,50].
The bivalent nanobody-PS in this study was verified to be biparatopic
and, led to a higher internalization rate constant of the HER2, in
comparison to a monovalent counterpart (Fig. S3). Even though the
biparatopic format was more effective in vitro, i.e. lead to 2–3 times
lower LD50, no significant differences between 1D5-PS and 1D5-18A12-
PS mediated PDT were observed when treated cells were exposed to
Annexin-V or propidium iodide staining. The rapid damage observed
combined with propidium iodide staining suggests necrosis, although
the majority of cells appear positive for Annexin-V (Fig. 3). We however
cannot exclude, other mechanisms of cell death following nanobody-
targeted PDT. Furthermore, the damage inflicted on the cell membrane
upon illumination could possibly expose phosphatidylserine, thereby
leading to Annexin-V staining, without necessarily triggering apoptotic
cell death. Consequently, no quantification of necrotic or apoptotic cells
was attemped in the present study and the emphasis was directed to the
observation of mixed events.
The optimal time interval for illumination was determined by
quantitative in vivo fluorescence spectroscopy which determines the
intrinsic fluorescence corrected for the influence of tissue optical
properties [47]. Quantitative spectroscopy showed the highest uptake
of nanobody-PS in high HER2 expressing tumors and not in the normal
mammary gland, in the skin, nor in the low HER2 expressing tumors,
supporting tumor-cell association of the conjugates, rather than pre-
sence in the vasculature (i.e. bloodstream). It is important to note that
fiber optic spectroscopy does not reveal information on the cellular
distribution of PS and is unable to effectively monitor the microscopic
vasculature in vivo. Although we have not yet conducted intravital
microscopy studies with the breast cancer model presented here, we can
expect some association of the conjugates with the vasculature of the
tumors, as we recently observed for nanobodies targeting EGFR [52].
Nevertheless, this association is likely not pronounced as no significant
accumulation at the tumor was observed for the low HER2 expressing
model, either through fluorescence spectroscopy (Fig. 4A) or non-in-
vasive imaging with the Pearl Imaging System (Fig. 4B). Although no
further quantitative biodistribution was performed in this study, the
fluorescence detected in kidneys, bladder and liver correlates with the
biodistribution profile of other near-infrared-labeled nanobodies
[45,53].
The highest intrinsic fluorescence in HER2-positive tumors was
obtained with 1D5-PS, demonstrating 1D5-PS as the leading nanobody
to carry PS to the tumor. In our previous nanobody-targeted PDT study,
the monovalent and biparatopic nanobody were administrated in equal
amounts (micrograms) of nanobody and equal molar amounts of PS, but
with a difference in degree of conjugation (thus, twice as many mole-
cules of monovalent compared to biparatopic nanobody). This resulted
in an approximately 2-fold difference in fluorescence intensity in favor
of the biparatopic nanobody-PS [25]. As the degree of conjugation of
the monovalent and biparatopic nanobody-PS was the same in the
present study (allowing the injection of the same number of molecules
of monovalent and biparatopic nanobody, although different amounts
in μg), the smaller size of the monovalent nanobody-PS possibly led to a
better distribution within the tumor [54], thus resulting in higher in-
trinsic fluorescence values. It is well recognized that the actual amount
of PS in the tissue predominantly determines the phototoxic effect.
Therefore, local illumination at the tumor was applied 2 h post injection
of the nanobody-PS conjugates, when the concentration of the PS was at
maximum. After PDT, to a dose of 100 J∙cm−2 at 50 mW∙cm−2 we
observed IRDye700DX photobleaching, as there was clearly less fluor-
escence seen with the Pearl Imaging System in the treated tumor in
comparison to the non-treated tumor (Fig. S6B). We believe that this is
the first report of this effect in vivo for IRDye700DX. PS photobleaching
during PDT has been extensively investigated for other PS and has been
shown in some cases to be useful for monitoring PDT efficacy [55].
Remarkably, single treatment with both nanobody-PS showed a
significant regression of high HER2 expressing tumors. There was no
significant difference between the regression of these tumors during the
30 days post illumination, when those received either 1D5-PS or 1D5-
18A12-PS, although the regression was higher after 1D5-PS PDT. This is
consistent with the higher fluorescence intensity of 1D5-PS in HCC1954
tumors, compared to the fluorescence of 1D5-18A12-PS. In contrast, in
the low HER2 expressing tumors, only a small growth delay was ob-
served. This short growth arrest is supported by the low Ki67 staining
observed 24 h post PDT (Fig. S7). The combination of the presence of
low HER2 expression and possible vascular effect of PDT may explain
this small effect in vivo, where in vitro there is no effect on cell viability.
The short-term effect of HER2-targeted PDT on low HER2 expressing
tumors is suggested to be mild, since these tumors recovered and con-
tinued to grow at the similar rate as the non-treated MCF-7 tumors. The
expression level of the target, although not the unique factor, as cells
can be more or less resistant to reactive oxygen species or more or less
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protected from apoptosis [56], is certainly critical for the success of the
treatment, as already previously suggested [25,26].
In our previous studies, although in vitro PDT mediated by bipar-
atopic anti-EGFR nanobody (7D12-9G8-PS) showed a more toxic effect
than the monovalent nanobody (7D12-PS), in vivo efficacy studies
showed a slightly higher phototoxicity induced by the monovalent
nanobody-PS conjugates [24]. The present study further supports these
observations as the most effective treatment in vivo was obtained with
the monovalent nanobody-PS, although differences were not sig-
nificant. This effect is likely due to the fact that, in small monovalent
nanobodies, the PS is closer to the cell membrane, and perhaps even
more important, it possesses better penetration into the interior of tu-
mors, leading to increased phototoxicity in vivo [51]. Thus, while in-
ternalization of the PS does not seem to be essential for in vivo efficacy,
an effective and homogenous tumor distribution of the nanobody-PS
conjugate is likely to have a higher impact. Still, we cannot exclude that
the better treatment response of the monovalent nanobody-PS is in
some extent related to the slightly smaller size of the tumors at the day
of treatment. Besides, no therapeutic effect is expected from the na-
nobody-PS conjugates alone, considering they are only administered
once and have a very short half-live.
Previous in vivo HER2-targeted PDT studies have been mainly per-
formed using subcutaneous tumor models (instead of orthotopic
models) and antibodies, showing only a restricted growth delay and no
regression in size of HER2-positive tumors [57–59]. These studies were
performed with comparable amount of antibody-PS (in the range of
100–200 μg) and light dose (100 J∙cm−2), while using higher fluence
rates (150–300 mW∙cm−2), repetitive drug administration, a longer
time period between injection and light illumination of days, and
multiple cycles of light illumination. Others achieved significant re-
duction of tumor volume of HER2-positive gastric cancers (of NCI-N87
and N87-GFP cell lines) with trastuzumab-PS mediated PDT (using the
same PS as in our studies) [60,61]. Although no direct comparison was
investigated with trastuzumab-PS in our study, the light exposure and
PS conjugates conditions in these studies were similar to our study;
however, all tumors regrew within 21 days, or light was applied mul-
tiple times a week for three weeks. The application of light multiple
times over days is clinically not always applicable in patients with
breast cancer: the light of a laser has a penetration depth suitable for
the illumination of superficial tumors and thus deeper tumors should be
exposed during an operation. To further minimize the number of ani-
mals used and avoid unnecessary repetitive studies, no control group
with trastuzumab alone was included [62]. Considering the previous in
vivo HER2-targeted PDT studies showing only a restricted growth delay
and no regression in size of HER2-positive tumors [59–61,63], the
unprecedented results reported in this study are certainly encouraging,
as our data show significant tumor regression after a single nanobody-
targeted PDT treatment, with a single light application. Yet, it would be
interesting to investigate the nanobody-targeted PDT in a more ag-
gressive tumor type.
Furthermore, additional in vivo studies which could contribute to an
optimized treatment relate to: testing of different light fluences and
fluence rates, to minimize side-effects (normal skin damage) even fur-
ther and possibly enhance efficacy. To explore more about the direct
effect of PDT on the vasculature, intravital microscopy imaging could
be used to provide longitudinal information on the kinetics and loca-
lization of the anti-HER2 nanobody-PS in detail [52]. To investigate
complete tumor remission, a longer follow-up of 90 days would be
necessary, and, it could also be interesting to investigate our model in
immunocompetent mice, as PDT has a strong immune component and
the requirement of the immune system for avoiding relapse from cancer
is becoming evident [64–67]. Nevertheless, for a more clinically re-
levant context, nanobody-targeted PDT could be investigated in the
postsurgical setting, for HER2-positive breast cancer in primary tumors,
which did not respond to neoadjuvant therapy and/or became resistant
to trastuzumab, compared to standard clinical treament.
In this study, a human orthotopic tumor model was developd in
mice and the used nanobody-PS conjugates do not bind to murine
HER2. In humans, normal tissue may also express HER2, which might
influence the quality of imaging and the effect of photodynamic
therapy. However, only very low expression of HER2 is seen in normal
human tissue, whereas HER2-positive breast tumors can have an in-
crease up to 40–100 fold in HER2 protein, resulting in 2 million re-
ceptors expressed at the tumor cell surface [68,69]. This high tumor-to-
normal ratio in humans will presumably ensure minimal uptake or ef-
fect in benign tissue, which is further warranted by the local illumi-
nation necessary to induce cytotoxicity.
Importantly, nanobodies have been approved for clinical use by the
European Medicines Agency and recently also by the Food and Drug
Administration as antithrombotic agents [44–46]. In oncology, clinical
evaluation of nanobodies as imaging agents has been initiated by
Keyaerts et al. The 68Ga-HER2 nanobody for PET/CT imaging has
shown high tracer accumulation in HER2-positive metastases [34].
Additionally, targeted PDT is currently being investigated in a phase I/
II trial, testing the EGFR-targeted antibody-PS conjugate RM1929,
containing cetuximab and IRDye700DX, in patients with recurrent head
and neck cancer. RM1929 has been shown to be safe and well tolerated,
and promising results with improved complete response and disease
control rate were seen (ClinicalTrials.gov Identifier: NCT02422979,
data not yet published). One of the major disadvantages of current
clinically approved PS is their spectral properties, compelling the PS
excitation with light below 660 nm, which results in light penetration of
a few millimetres [63,70]. The fluorescent properties of near-infrared
IRDye700DX, which allows deeper tissue penetration, makes it a very
interesting molecule as it could be employed both for diagnosis and
treatment. In vivo data already demonstrated that IRDye700DX can
safely be used for intraoperative tumor localization using near-infrared
imaging [71,72]. In a clinical setting, such nanobody-PS conjugates
could be employed first for fluorescence-guided surgery and assist the
surgeon in its resection and secondly, upon light exposure of the wound
bed, to destroy possible remaining cancer cells and potentially acti-
vating the immune system. The decrease in fluorescence of the con-
jugate can likely be used to monitor the efficacy of PDT and the re-
sponse of tumors [59]. The fact that both IRDye700DX and nanobodies
have already reached the clinic, suggests a smooth translation of na-
nobody-targeted PDT into clinical practice, to further improve current
clinical PDT and provide additional treatment options to HER2-posi-
tive, and in particular trastuzumab-resistant patients.
In this study we present a nanobody-based strategy to treat not only
trastuzumab-sensitive HER2-positive breast cancer, but also trastu-
zumab-resistant breast cancer. The mechanisms of resistance to tras-
tuzumab are mostly related to an inactive target receptor by lacking of
extracellular binding to domain IV. Binding of other anti-HER2 drugs,
as nanobody-drug conjugates, against different epitopes present in the
HER2 extracellular domain could provoke an anti-tumor effect in the
presence of trastuzumab-resistance. As the HER2 expression levels vary
in breast cancer patients, it remains to be elucidated which patients
would benefit most from nanobody HER2-targeted PDT. In the clinical
setting, HER2-targeted nanobody-PS conjugates could facilitate fluor-
escence-guided resection and targeted PDT of primary HER2-positive
tumors. Intraoperatively, due to chemotherapy-induced fibrosis, it can
be difficult to distinguish between tumor or benign tissue and obtain
clear resection margins [73,74]. HER2-enriched tumors even have the
highest risk of local recurrence after breast-conserving surgery [75,76].
Neoadjuvant systemic chemotherapy plus dual-agent HER2 blockade
with complementary mechanisms of action, improved the number of
proportion of patients achieving pathological response, however with
increased toxicity [10,14]. Anti-HER2 nanobody-targeted PDT could be
employed to prevent disease recurrence by optimising the number of
HER2-positive early breast cancer patients with no residual cancer,
without imparting toxicity of additional chemotherapy. Also for pa-
tients whose tumors are or become resistant to trastuzumab(−based)
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therapy, anti-HER2 nanobody-targeted PDT could be a viable option. In
the particular case of trastuzumab-resistant patients with metastasis,
one could foresee the usage of nanobodies targeting HER2 as carriers of
drugs or toxic compounds (such as nanobody-drug conjugates) [77–81],
although this remains to be further investigated.
The development of combined imaging and therapeutic approaches
(designated theranostics) for HER2 overexpressing breast cancer pa-
tients is of great importance, as it would simultaneously allow the di-
agnosis and subsequent treatment of HER2-positive lesions.
Furthermore, with HER2 overexpression in many other cancers, in-
cluding oesophageal, gastric, bladder and endometrial cancers [82,83],
our anti-HER2 nanobody-targeted PDT constitutes a promising treat-
ment option to be used across multiple histologically different cancers
indications. Especially, for tumors of the gastrointestinal tract where
minimally invasive surgery is performed using a laparoscope or endo-
scope, our nanobody-PS conjugates could provide the opportunity to
perform fluorescence imaging and PDT using fiber-optics.
In conclusion, we have developed HER2-targeted nanobody-PS
conjugates and for the first time demonstrated significant tumor re-
gression after a single treatment session. Besides combining fluores-
cence imaging with therapy, this could easily be implemented into
current clinical regimens, to successfully treat trastuzumab-resistant
and -sensitive HER2-positive breast cancer.
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